You are here
Medicines Safety Update Vol 2, No 6, December 2011
This issue of Medicines Safety Update was published in the December 2011 issue of Australian Prescriber.
In this issue:
Proton pump inhibitors and acute interstitial nephritis
The incidence of acute interstitial nephritis caused by proton pump inhibitors (PPIs) is unknown. Given the widespread and growing use of PPIs and the consequences of acute interstitial nephritis, the potential for this adverse reaction should not be forgotten.
PPIs are a leading cause of drug-induced acute interstitial nephritis (AIN), which may cause acute kidney injury and sometimes long-term damage.1 The association between PPIs and interstitial nephritis was reported by the TGA in the Australian Adverse Drug Reactions Bulletin in 1995 and in 2003.2,3
Reports continue to be received of interstitial nephritis with PPI use. The table shows reports to the TGA and the World Health Organization's (WHO) Program for International Drug Monitoring* to July 2011 of suspected cases of interstitial nephritis in which a PPI was suspected. These data should not be taken to reflect incidence rates.
|omeprazole||54 (from 1990)||293 (from 1993)|
|lansoprazole||0 (from 1994)||23 (from 1996)|
|pantoprazole||21 (from 1995)||84 (from 1998)|
|rabeprazole||28 (from 2001)||54 (from 2000)|
|esomeprazole||28 (from 2002)||44 (from 2002)|
The total number of PBS/RPBS prescriptions dispensed since 1992 for each PPI have been: omeprazole 50.1 million; lansoprazole 10.2 million; pantoprazole 29.6 million; rabeprazole 15.3 million; and esomeprazole 38.2 million. PPIs are also available for direct purchase by consumers.
Product Information documents for PPIs mention interstitial nephritis as a very rarely or rarely reported event in the postmarketing experience with these drugs. Fever and skin rash are also sometimes mentioned but patients with PPI-induced AIN rarely present with the classic hypersensitivity syndrome of fever, skin rash and eosinophilia in the context of renal impairment.4 Non-specific symptoms such as fever, anorexia, weight loss, fatigue, lethargy, nausea, vomiting and malaise predominate. Laboratory findings include pyuria, proteinuria and/or haematuria.1
While AIN is considered a class effect of PPIs, the TGA has received no reports of interstitial nephritis with lansoprazole. The lack of reports may reflect the lower use of lansoprazole compared with other PPIs, but could possibly reflect variation in the incidence of rare adverse reactions within a class. Prescribers should be aware of the possibility of AIN with this class of medicine. If cases are suspected, please report them to the TGA - see 'What to report' on page 193.
- Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 2006;4:597-604.
- Omeprazole and interstitial nephritis. Aust Adv Drug React Bull 1995;14:15.
- Interstitial nephritis with the proton pump inhibitors. Aust Adv Drug React Bull 2003;22:2.
- Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol 2010;6:461-70.
* Adverse drug reaction information from this Program is not homogeneous at least with respect to origin or likelihood that the pharmaceutical product caused the adverse reaction and the information does not represent the opinion of the World Health Organization
Dabigatran (Pradaxa) and the risk of bleeding
Dabigatran (Pradaxa) is a potent short-acting anticoagulant for which there is no antidote or reversal agent. As with warfarin, bleeding events can occur. Clinicians are urged to give careful consideration to the suitability of their patients for dabigatran particularly with regard to recognised risks of bleeding.
|Type of adverse event||Number|
|Total adverse events||297|
|Serious adverse events||196|
|Serious bleeding adverse events||70|
|Serious gastrointestinal bleeding||48|
|Serious intracranial bleeding||6|
|Events in patients aged 75 years or older|
|Total adverse events||166|
|Serious adverse events||108|
Dabigatran (Pradaxa) is a potent oral anticoagulant. It is a direct thrombin inhibitor that inhibits free and clot-bound thrombin. It has a mean half-life of 12-17 hours. It is renally excreted and the rate of elimination is related to renal function. There is a close correlation between plasma dabigatran levels and anticoagulant effect.
Dabigatran may be considered an alternative to warfarin and it carries similar risks of bleeding. In clinical trials the risk of bleeding per year of treatment with dabigatran was 16.6% (1 in 6 patients) when taking 150 mg twice daily, and 14.7% (1 in 6.8 patients) taking 110 mg twice daily compared with 18.4% (1 in 5.4 patients) for warfarin.
Bleeding adverse events with dabigatran
In April 2011 the TGA approved dabigatran for use for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and at least one risk factor for stroke. Since then, the TGA has received an increase in the number of bleeding-related adverse events reports for dabigatran (see table).
The analysis of these reports shows that some of the bleeding adverse events occurred during the transition from warfarin to dabigatran; many of the adverse events are occurring in patients on the reduced dosage regimen; and the most common site of serious bleeding for dabigatran is the gastrointestinal tract, whereas for warfarin it is intracranial.
Risk factors for bleeding
- Age ≥ 75 years
- Moderate renal impairment (30–50 mL/min) – severe renal impairment is a contraindication
- Concomitant use of aspirin (approximately twice the risk), clopidogrel (approximately twice the risk), non-steroidal anti-inflammatory drugs including COX-2 inhibitors
Monitoring renal function
New recommendations for assessing renal function before starting dabigatran and during its use are now in place. See information on the TGA website at Current year alerts.
In bleeding patients Thrombin Time is the most readily available clotting test reflective of the relationship between dabigatran concentration and clotting time. Although there is not a direct linear relationship, activated Partial Thromboplastin Time (aPTT) >80 seconds is associated with a higher bleeding risk. Prothrombin time (INR) should not be used.
Guidelines for managing bleeding patients
Australian experts are currently developing Australian guidelines for the management of bleeding in patients taking dabigatran. In the meantime clinicians are referred to the New Zealand guidelines.1
It is strongly recommended that clinicians read the Product Information before prescribing dabigatran. The Product Information is available from the TGA website.2 For more detailed information regarding the considerations of the TGA in approving dabigatran please see the Australian Public Assessment Report (AusPAR).3
Reporting adverse events
Health professionals are requested to report adverse events associated with dabigatran to the TGA via the TGA website.
- Guidelines for management of bleeding with dabigatran (pdf,86kb). New Zealand: PHARMAC; 2011 Aug. [cited 2011 Nov 8]
- Pradaxa Product Information. Boehringer Ingelheim Pty Limited. 2011 August.
- Dabigatran etexilate mesilate - AusPAR. Therapeutic Goods Administration. 2011 May 24.
Risk of myopathy and rhabdomyolysis with simvastatin – new dosage recommendations and contraindications
To reduce the risk of myopathy and rhabdomyolysis, health professionals are advised of new recommendations to limit the use of high dose simvastatin (80 mg/day) and of new contraindications for the use of simvastatin with potent CYP3A4 inhibitors, gemfibrozil, cyclosporin or danazol (see box). They are also reminded of the need for lower doses when simvastatin is used concomitantly with drugs that interact with simvastatin and increase its absorption.
Simvastatin, like other inhibitors of HMG-CoA reductase, is known to cause myopathy and more rarely rhabdomyolysis. The risk of myopathy is dose related and is more likely to occur in the first year of treatment. Other risk factors include age ≥65 years, female gender, uncontrolled hypothyroidism and renal impairment. Myopathy can be the result of interactions with other drugs. Many cases may be associated with a genetic variant which results in reduced uptake of simvastatin by the liver.
A recent re-analysis by the US Food and Drug Administration of the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) trial has confirmed the increased risk of myopathy and rhabdomyolysis with increasing doses of simvastatin.1 In the trial the incidence of myopathy increased from 0.02% among patients taking 20 mg of simvastatin daily to 0.9% among those taking 80 mg daily. The trial also found only a limited increase in benefit from the 80 mg dose compared with lower doses.
Following a review of these findings, the TGA is recommending limitations to the use of high dose simvastatin (80 mg/day) and changes to the contraindications. The TGA is working with the sponsors of simvastatin and simvastatin-containing medications to update the Product Information to provide increased warnings regarding the risk of myopathy associated with high doses of simvastatin, and to detail the new dosage recommendations and contraindications (see box).
Important information for health professionals
The 80 mg/day dose of simvastatin should only be used in patients at high risk of cardiovascular complications who have not achieved their treatment goals on lower doses and when the benefits are expected to outweigh the potential risks.
Concomitant administration of simvastatin with potent CYP3A4 inhibitors, gemfibrozil, cyclosporin, or danazol is now contraindicated (see box for details).
Simvastatin is contraindicated in patients who have previously experienced myopathy secondary to other lipid lowering agents.
In patients taking simvastatin for whom an interacting agent is needed, a lower dose of simvastatin or an alternative statin with less potential for drug-drug interactions should be used.
Health professionals should advise patients who are commencing simvastatin therapy or whose dose is being increased of the risk of myopathy and remind patients to report any unexplained muscle pain, tenderness or weakness to a health professional promptly.
Simvastatin therapy should be discontinued immediately if myopathy is suspected.
Health professionals are asked to report any suspected cases of myopathy to the TGA.
|Risk of myopathy/rhabdomyolysis|
|The risk of myopathy is greater in patients on simvastatin 80 mg compared with other statin-based therapies with similar LDL-C lowering efficacy|
|New dose recommendation|
|The 80 mg/day dose of simvastatin should only be used in patients at high risk of cardiovascular complications who have not achieved their treatment goals on lower doses and when the benefits are expected to outweigh the potential risks|
Concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, posaconazole, HIV protease inhibitors, erythromycin, clarithromycin, telithromycin and nefazodone). If treatment with these medicines is unavoidable, simvastatin should be suspended during the course of treatment.
Concomitant administration of gemfibrozil, cyclosporin or danazol.
|Precautions - interactions with other medicines|
Amiodarone: the dose of simvastatin should not exceed 20 mg daily in patients receiving concomitant medication with amiodarone.
Calcium channel blockers:
Moderate inhibitors of CYP3A4: patients taking other medicines labelled as having a moderate inhibitor effect on CYP3A4 concomitantly with simvastatin, particularly higher simvastatin doses, may have an increased risk of myopathy.
Other fibrates: concomitant use of gemfibrozil is contraindicated. The concomitant use of simvastatin and other fibrates should be avoided.
Niacin (≥1 g/day): the dose of simvastatin should not exceed 20 mg daily in patients receiving concomitant medication with niacin (nicotinic acid) ≥1 g/day.
Colchicine: there have been reports of myopathy and rhabdomyolysis with the concomitant administration of colchicine and simvastatin in patients with renal insufficiency. Close clinical monitoring of patients taking this combination is advised.
* These updates provide information on changes to the recommendations for simvastatin. For full prescribing information, see the Zocor Product Information available on the TGA website.
- Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. US Food and Drug Administration. 8 June 2011. [cited 2011 Nov 8]
Medicines Safety Update is written by staff from the Office of Product Review. Editor: Dr Katherine Gray. Principal Medical Advisor: Dr Megan Keaney. Contributors to this issue include Dr Nick Simpson, Dr Kaye Robertson and Dr Bronwen Harvey.
For correspondence or further information about Medicines Safety Update, contact the TGA's Office of Product Review at ADR.Reports@tga.gov.au or 1800 044 114.
What to report? (you do not need to be certain, just suspicious!)
The TGA encourages the reporting of all suspected adverse reactions to medicines, including vaccines, over-the-counter medicines, herbal, traditional or alternative remedies. The TGA particularly requests reports of:
- ALL suspected reactions to new medicines
- ALL suspected medicines interactions
- Suspected reactions causing
- admission to hospital or prolongation of hospitalisation
- increased investigations or treatments
- birth defects
For blue cards
Reports of suspected adverse drug reactions are best made by using a prepaid reporting form ('blue card') which is available from the website: Report of suspected adverse reaction to medicines/vaccines or from the Office of Product Review, phone 1800 044 114.
Reports can also be submitted:
- online - on the TGA website and click on 'Report a problem' on the right
- fax 02 6232 8392
- email ADR.Reports@tga.gov.au
For further information from the Office of Product Review:
- Phone: 1800 044 114
- Fax: 02 6232 8392
- Email: ADR.Reports@tga.gov.au
© Commonwealth of Australia 2011
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <firstname.lastname@example.org>.